| 000 | 01230 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250515210051.0 | ||
| 264 | 0 | _c20100427 | |
| 008 | 201004s 0 0 eng d | ||
| 022 | _a1432-0584 | ||
| 024 | 7 |
_a10.1007/s00277-010-0907-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCarella, A M | |
| 245 | 0 | 0 |
_aHypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias? _h[electronic resource] |
| 260 |
_bAnnals of hematology _cJun 2010 |
||
| 300 |
_a531-3 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 | _aModels, Theoretical |
| 650 | 0 | 4 | _aNeoadjuvant Therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-abl _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRisk Factors |
| 773 | 0 |
_tAnnals of hematology _gvol. 89 _gno. 6 _gp. 531-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00277-010-0907-3 _zAvailable from publisher's website |
| 999 |
_c19535382 _d19535382 |
||